The nasal spray vaccine jointly developed by a team led by Chair Professor Yuan Guoyong of the Department of Microbiology of the University of Hong Kong’s Faculty of Medicine, Xiamen University and Beijing Wantai Biotech has been approved by the State Drug Administration for emergency use in the Mainland. The University of Hong Kong revealed that Wantai Bio plans to produce 200 million doses of nasal spray vaccines in the next six months.
In addition, the number of confirmed cases of new coronary pneumonia in Hong Kong in a single day continued to hover at the level of nearly 10,000, with an increase of 9,508 cases yesterday, including 665 imported cases. The Center for Health Protection announced that 27 residential care homes for the elderly and the disabled recorded a total of 45 positive cases among residents and 10 staff yesterday, and 82 residents needed to be quarantined.
In terms of schools, a total of 23 classes in 22 schools had to suspend face-to-face teaching for a week due to clustered cases. Twenty more patients, aged between 64 and 97, died yesterday, and a 22-month-old boy, who was announced a few days ago, is still in critical condition.
Originally published on AM730 https://www.am730.com.hk/Local/Hong Kong University develops nasal spray vaccine-FDA approves emergency use in the Mainland/351338?utm_source=yahoorss&utm_medium=referral
